Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC). Its earlier-stage pipeline includes preclinical compounds that the Company is evaluating in multiple rare diseases of unmet medical need, including methicillin-resistant staph aureus and NTM. Its earlier clinical-stage pipeline includes INS1007 and INS1009. INS1007 is an oral, reversible inhibitor of dipeptidyl peptidase 1. INS1009 is an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. It has completed a Phase I study of INS1009.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:INSM
- CUSIP: N/A
- Web: www.insmed.com
Capitalization:- Market Cap: $1.07478 billion
- Outstanding Shares: 62,090,000
Average Prices:- 50 Day Moving Avg: $16.71
- 200 Day Moving Avg: $16.41
- 52 Week Range: $10.21 - $19.35
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -8.30
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $1.96 per share
- Price / Book: 8.85
Profitability:- EBIDTA: ($173,660,000.00)
- Return on Equity: -96.79%
- Return on Assets: -71.00%
Debt:- Debt-to-Equity Ratio: 0.45%
- Current Ratio: 5.66%
- Quick Ratio: 5.66%
Misc:- Average Volume: 379,448 shs.
- Beta: 0.69
- Short Ratio: 8.96
Frequently Asked Questions for Insmed (NASDAQ:INSM)
What is Insmed's stock symbol?
Insmed trades on the NASDAQ under the ticker symbol "INSM."
How were Insmed's earnings last quarter?
Insmed, Inc. (NASDAQ:INSM) announced its quarterly earnings data on Wednesday, May, 3rd. The company reported ($0.60) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.60). View Insmed's Earnings History.
When will Insmed make its next earnings announcement?
Where is Insmed's stock going? Where will Insmed's stock price be in 2017?
5 brokerages have issued twelve-month price objectives for Insmed's shares. Their forecasts range from $17.00 to $27.00. On average, they expect Insmed's share price to reach $22.75 in the next year. View Analyst Ratings for Insmed.
Who are some of Insmed's key competitors?
Some companies that are related to Insmed include Spark Therapeutics (ONCE), Aerie Pharmaceuticals (AERI), Loxo Oncology (LOXO), Halozyme Therapeutics (HALO), Radius Health (RDUS), Lexicon Pharmaceuticals (LXRX), NovoCure Limited (NVCR), Array BioPharma (ARRY), Dermira (DERM), Acceleron Pharma (XLRN), Amarin Corporation PLC (AMRN), Xencor (XNCR), Clinigen Group PLC (CLIN), Forward Pharma A/S (FWP), Omeros Corporation (OMER), Acorda Therapeutics (ACOR), Aduro Biotech (ADRO) and Synergy Pharmaceuticals (SGYP).
Who are Insmed's key executives?
Insmed's management team includes the folowing people:
- William H. Lewis, President, Chief Executive Officer, Director
- Paolo Tombesi, Chief Financial Officer
- Orlov S Nicole Schaeffer, Senior Vice President- Human Resource and Corporate Services
- Eugene Jeffrey Sullivan M.D., Chief Product Strategy Officer and Chief Scientific Officer
- Peggy J. Berry, Vice President- Regulatory Affairs
- Mark Quigley, Vice President- Quality Assurance
- Christine A. Pellizzari, General Counsel, Corporate Secretary
- Roger Adsett, Chief Commercial Officer
- Paul Streck, Chief Medical Officer
- Donald J. Hayden Jr., Non-Executive Chairman of the Board
Who owns Insmed stock?
Insmed's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Franklin Street Advisors Inc. NC (0.06%). Company insiders that own Insmed stock include Andrew T Drechsler, Christine A Pellizzari, Donald J Hayden, Jr, Myrtle S Potter, Orlov S Nicole Schaeffer and William Lewis. View Institutional Ownership Trends for Insmed.
How do I buy Insmed stock?
Shares of Insmed can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Insmed's stock price today?
One share of Insmed stock can currently be purchased for approximately $17.35.
MarketBeat Community Rating for Insmed (NASDAQ INSM)MarketBeat's community ratings are surveys of what our community members think about Insmed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Insmed (NASDAQ:INSM) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 4 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.80) |
| Consensus Price Target: | $22.75 (31.12% upside) |
Analysts' Ratings History for Insmed (NASDAQ:INSM)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/10/2017 | Robert W. Baird | Initiated Coverage | Outperform -> Outperform | $23.00 | Medium |  |
| 6/11/2017 | Citigroup Inc. | Reiterated Rating | Neutral | $14.00 -> $17.00 | High | |
| 5/1/2017 | Stifel Nicolaus | Boost Price Target | Buy | $23.00 -> $27.00 | Medium | |
| 11/4/2016 | HC Wainwright | Reiterated Rating | Buy | | N/A | |
| 8/21/2016 | Piper Jaffray Companies | Set Price Target | Buy | $24.00 | N/A | |
| 4/17/2016 | Cowen and Company | Reiterated Rating | Buy | | N/A | |
| 2/26/2016 | Leerink Swann | Lower Price Target | Outperform | $29.00 -> $23.00 | N/A | |
(Data available from 7/25/2015 forward)
Earnings History for Insmed (NASDAQ:INSM)Earnings History by Quarter for Insmed (NASDAQ INSM)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/2/2017 | | | | | | | | |
| 5/3/2017 | Q1 2017 | ($0.60) | ($0.60) | $0.30 million | | View | Listen | |
| 2/23/2017 | Q316 | ($0.89) | ($1.10) | $0.30 million | | View | N/A | |
| 11/3/2016 | Q216 | ($0.59) | ($0.61) | $0.10 million | | View | N/A | |
| 8/4/2016 | Q2 | ($0.56) | ($0.59) | | | View | N/A | |
| 5/5/2016 | Q1 | ($0.56) | ($0.54) | | | View | N/A | |
| 2/25/2016 | Q415 | ($0.49) | ($0.51) | | | View | N/A | |
| 11/6/2015 | Q315 | ($0.48) | ($0.50) | | | View | N/A | |
| 8/6/2015 | Q2 | ($0.48) | ($0.47) | | | View | N/A | |
| 5/7/2015 | Q115 | ($0.49) | ($0.55) | | | View | N/A | |
| 2/27/2015 | Q414 | ($0.57) | ($0.36) | | | View | N/A | |
| 11/6/2014 | Q314 | ($0.51) | ($0.54) | | | View | N/A | |
| 8/6/2014 | Q214 | ($0.50) | ($0.59) | | | View | N/A | |
| 5/8/2014 | Q114 | ($0.39) | ($0.36) | | | View | N/A | |
| 3/6/2014 | Q413 | ($0.45) | ($0.41) | | | View | N/A | |
| 11/5/2013 | Q313 | ($0.41) | ($0.46) | | | View | Listen | |
| 8/6/2013 | Q2 2013 | ($0.32) | ($0.28) | $5.38 million | | View | Listen | |
| 5/7/2013 | Q1 2013 | ($0.46) | ($0.43) | | | View | Listen | |
| 11/7/2012 | Q312 | ($0.42) | ($0.38) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Insmed (NASDAQ:INSM)2017 EPS Consensus Estimate: ($2.40)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.58) | ($0.58) | ($0.58) |
| Q2 2017 | 1 | ($0.63) | ($0.63) | ($0.63) |
| Q3 2017 | 1 | ($0.59) | ($0.59) | ($0.59) |
| Q4 2017 | 1 | ($0.60) | ($0.60) | ($0.60) |
(Data provided by Zacks Investment Research)
Dividend History for Insmed (NASDAQ:INSM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Insmed (NASDAQ:INSM)Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 92.00%
Insider Trades by Quarter for Insmed (NASDAQ:INSM)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/31/2017 | Christine A Pellizzari | General Counsel | Buy | 10,000 | $15.14 | $151,400.00 | |
| 12/15/2016 | Christine A Pellizzari | General Counsel | Buy | 20,000 | $12.81 | $256,200.00 | |
| 12/14/2016 | Myrtle S Potter | Director | Sell | 6,466 | $12.79 | $82,700.14 | |
| 11/14/2016 | Andrew T Drechsler | CFO | Sell | 45,000 | $14.67 | $660,150.00 | |
| 11/9/2016 | Orlov S Nicole Schaeffer | SVP | Sell | 68,774 | $11.95 | $821,849.30 | |
| 2/1/2016 | William Lewis | CEO | Buy | 50,000 | $13.34 | $667,000.00 | |
| 9/2/2015 | Donald J. Hayden, Jr. | Director | Sell | 25,000 | $24.06 | $601,500.00 | |
| 5/12/2015 | Mark Quigley | VP | Sell | 18,750 | $22.07 | $413,812.50 | |
| 8/13/2014 | Melvin Md Sharoky | Director | Buy | 88,889 | $11.25 | $1,000,001.25 | |
| 11/1/2013 | William Lewis | CEO | Buy | 5,233 | $14.28 | $74,727.24 | |
| 7/22/2013 | Fmr Llc | Insider | Sell | 158,758 | $12.02 | $1,908,271.16 | |
| 7/18/2013 | Fmr Llc | Insider | Sell | 310,227 | $11.49 | $3,564,508.23 | |
| 7/15/2013 | Fmr Llc | Insider | Sell | 161,531 | $10.79 | $1,742,919.49 | |
| 7/9/2013 | Fmr Llc | Insider | Sell | 146,599 | $10.01 | $1,467,455.99 | |
| 7/3/2013 | Fmr Llc | Insider | Sell | 365,779 | $9.96 | $3,643,158.84 | |
| 7/1/2013 | William Lewis | CEO | Buy | 7,585 | $9.83 | $74,560.55 | |
| 6/24/2013 | Fmr Llc | Insider | Sell | 50,000 | $12.00 | $600,000.00 | |
| 6/20/2013 | Fmr Llc | Insider | Sell | 143,088 | $12.24 | $1,751,397.12 | |
| 6/12/2013 | Fmr Llc | Insider | Sell | 85,758 | $13.00 | $1,114,854.00 | |
| 6/6/2013 | Fmr Llc | Insider | Sell | 130,557 | $12.85 | $1,677,657.45 | |
| 4/1/2013 | William Lewis | CEO | Buy | 9,816 | $7.58 | $74,405.28 | |
| 1/9/2013 | William Lewis | CEO | Buy | 10,770 | $6.90 | $74,313.00 | |
| 12/3/2012 | William Lewis | CEO | Buy | 13,568 | $7.36 | $99,860.48 | |
(Data available from 1/1/2013 forward)
Headline Trends for Insmed (NASDAQ:INSM)
Latest Headlines for Insmed (NASDAQ:INSM)
| Source: |
|
| Date | Headline |
|---|
 | Implied Volatility Surging For Insmed, Inc. (INSM) Stock Options - Nasdaq
www.nasdaq.com - July 18 at 2:23 AM |
 | Zacks Investment Research Downgrades Insmed, Inc. (INSM) to Hold
www.americanbankingnews.com - July 18 at 12:26 AM |
 | Implied Volatility Surging For Insmed, Inc. (INSM) Stock Options
www.zacks.com - July 17 at 8:24 AM |
 | Insmed to Host Analyst and Investor Day on July 19, 2017
finance.yahoo.com - July 13 at 3:20 AM |
| Insmed, Inc. (INSM) Coverage Initiated by Analysts at Robert W. Baird
www.americanbankingnews.com - July 10 at 7:14 PM |
| Insmed, Inc. (NASDAQ:INSM) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 7 at 10:50 AM |
 | Cystic Fibrosis Therapeutics Pipeline H1 2017 Research Report ... - PR Newswire (press release)
www.prnewswire.com - June 30 at 8:04 PM |
| Insmed, Inc. (INSM) Expected to Post Earnings of -$0.63 Per Share
www.americanbankingnews.com - June 30 at 11:23 AM |
| Options Traders Expect Huge Moves in Insmed (INSM) Stock
finance.yahoo.com - June 27 at 6:06 PM |
| BidaskClub Upgrades Insmed, Inc. (INSM) to "Hold"
www.americanbankingnews.com - June 23 at 8:20 PM |
| Insmed to Present at the JMP Securities Life Sciences Conference
finance.yahoo.com - June 13 at 10:52 AM |
| Insmed, Inc. (INSM) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - June 12 at 11:24 AM |
| Insmed Incorporated (INSM) Stock Rating Reaffirmed by Citigroup Inc.
www.americanbankingnews.com - June 11 at 7:40 PM |
 | Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire (press release)
globenewswire.com - June 8 at 6:55 PM |
| Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - June 8 at 6:55 PM |
| -$0.63 Earnings Per Share Expected for Insmed Incorporated (INSM) This Quarter
www.americanbankingnews.com - June 6 at 12:30 AM |
| Insmed Incorporated (INSM) Upgraded to Hold at ValuEngine
www.americanbankingnews.com - June 4 at 10:38 AM |
| Insmed Incorporated (INSM) General Counsel Acquires $151,400.00 in Stock
www.americanbankingnews.com - June 1 at 8:14 PM |
 | Form 8-K INSMED Inc For: May 15 - StreetInsider.com
www.streetinsider.com - May 20 at 5:44 PM |
 | BRIEF-Insmed Inc files for potential stock shelf offering
www.reuters.com - May 19 at 5:39 PM |
| Insmed Announces Key Additions to its Executive Management Team - GlobeNewswire (press release)
globenewswire.com - May 16 at 10:50 PM |
| -$0.62 EPS Expected for Insmed Incorporated (INSM) This Quarter
www.americanbankingnews.com - May 10 at 8:36 AM |
| Q2 2017 Earnings Forecast for Insmed Incorporated Issued By Leerink Swann (INSM)
www.americanbankingnews.com - May 8 at 8:21 AM |
| Insmed Incorporated (INSM) Releases Earnings Results, Hits Expectations
www.americanbankingnews.com - May 5 at 11:53 PM |
 | Best Biotech Stocks For Capital Gains In The Next 3 Months
seekingalpha.com - May 4 at 6:07 PM |
| BRIEF-Insmed reports Q1 loss per share $0.60
www.reuters.com - May 4 at 6:07 PM |
| Edited Transcript of INSM earnings conference call or presentation 3-May-17 12:30pm GMT
finance.yahoo.com - May 4 at 6:07 PM |
| Form 8-K INSMED Inc For: May 03 - StreetInsider.com
www.streetinsider.com - May 4 at 12:41 AM |
| Investor Network: Insmed Incorporated to Host Earnings Call
finance.yahoo.com - May 4 at 12:41 AM |
| Insmed Reports First Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - May 4 at 12:41 AM |
| Insmed reports 1Q loss
finance.yahoo.com - May 4 at 12:41 AM |
| Insmed (INSM) Given Coverage Optimism Score of 0.44
www.americanbankingnews.com - May 3 at 11:20 AM |
| Insmed Incorporated (INSM) Given Buy Rating at Stifel Nicolaus
www.americanbankingnews.com - May 1 at 3:02 PM |
| Insmed (INSM) Getting Positive News Coverage, Analysis Shows
www.americanbankingnews.com - April 30 at 10:51 AM |
| Implied Volatility Surging for Insmed (INSM) Stock Options - Nasdaq
www.nasdaq.com - April 29 at 9:11 AM |
| Implied Volatility Surging for Insmed (INSM) Stock Options
finance.yahoo.com - April 28 at 10:01 AM |
| Insmed (INSM) Earning Favorable Press Coverage, Report Finds
www.americanbankingnews.com - April 27 at 9:32 PM |
| Insmed to Host First Quarter 2017 Financial Results Conference Call on Wednesday, May 3, 2017 - Yahoo Finance
finance.yahoo.com - April 27 at 8:48 AM |
| Insmed to Present at the Deutsche Bank 42nd Annual Health Care Conference
finance.yahoo.com - April 27 at 8:48 AM |
| Insmed Incorporated (INSM) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 27 at 12:50 AM |
| Insmed Incorporated (INSM) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - April 27 at 12:28 AM |
| Insmed to Host First Quarter 2017 Financial Results Conference Call on Wednesday, May 3, 2017
finance.yahoo.com - April 26 at 7:24 PM |
| Insmed (INSM) Receives Daily Coverage Optimism Rating of -0.12
www.americanbankingnews.com - April 24 at 1:32 PM |
| First Week of November 17th Options Trading For Insmed (INSM)
www.nasdaq.com - April 20 at 6:02 PM |
| Insmed (INSM) Earning Favorable News Coverage, Study Finds
www.americanbankingnews.com - April 20 at 11:09 AM |
| Stifel Nicolaus Reiterates Buy Rating for Insmed Incorporated (INSM)
www.americanbankingnews.com - April 18 at 11:46 AM |
| Insmed Incorporated (INSM) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - April 9 at 9:32 PM |
| Do Options Traders Know Something About Insmed Incorporated (INSM) Stock We Don't? - Nasdaq
www.nasdaq.com - March 21 at 12:20 PM |
| Do Options Traders Know Something About Insmed Incorporated (INSM) Stock We Don't?
finance.yahoo.com - March 21 at 12:20 PM |
| Noteworthy Monday Option Activity: SMTC, ISRG, INSM
www.nasdaq.com - March 6 at 5:28 PM |
Insmed (INSM) Chart for Tuesday, July, 25, 2017
